Neuronetics Announces 510(k) Clearance of MT Cap Technology for NeuroStar® Advanced Therapy for Mental Health

NEXT STORY
Global Markets for Infectious Disease Treatments
PREV STORY
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

author_avatar
NASDAQ Market News

UPDATE – electroCore Appointments Multiple Industry Veterans to Key Management Positions

author_avatar
NASDAQ Market News

Basilea berichtet auf ASCO Gastrointestinal Cancers Symposium über Aktivität von Derazantinib in präklinischen Magenkrebs-Modellen

author_avatar
NASDAQ Market News